Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD )

Similar Items

• UK best practice recommendations for children and young people <18 years with pre‐stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED)
  by: Rachel E. J. Besser, et al.
  Published: (2025)
• Analysis of attitudes towards and experiences with physician Associates in Diabetes and Endocrinology from a survey of Association of British Clinical Diabetologists members
  by: Saika Hussain, et al.
  Published: (2024)
• Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study
  by: Harshal Deshmukh, et al.
  Published: (2024)
• Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
  by: Emma Watts, et al.
  Published: (2025)
• A UK healthcare professional survey on the islet autoantibody status of children and young people with pre‐stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes
  by: Rabbi Swaby, et al.
  Published: (2025)